TCF21, already identified as a candidate tumor suppressor, epigenetically inactivated in lung and head and neck cancers [32], has been recently included in an innovative panel of biomarkers for a simultaneous detection of urological cancers, providing 36% sensitivity and 100% specificity for kidney cancer detection [41]. The gene discussed is TCF21; the disease is head and neck cancer.